

Special Issue

Next-Generation Vaccines for Animal Infectious Diseases

Message from the Guest Editors

Vaccines play a pivotal role in safeguarding against animal infectious diseases, which not only impact global livestock production but also pose a risk to human health and security. Traditional vaccines, though effective in certain cases, face challenges in terms of safety, efficacy, and speed of deployment.

Nanovaccines offer enhanced efficacy and stability compared to traditional vaccines, owing to their precise targeting and controlled release mechanisms. These vaccines hold promise for the future, revolutionizing animal infectious disease prevention and control through improved immune response induction, broader pathogen coverage, and simplified administration protocols. This Special Issue cordially invites submissions of original research and review articles primarily focused on the preclinical and clinical development of vaccines in the field of prevention and control of animal infectious diseases, including LNP-mRNA vaccines, VLP vaccines, polymeric/inorganic nanoparticle vaccines, self-assembled protein vaccines, biomimetic nanoparticle vaccines, and so on.

Guest Editors

Dr. Yongwen Luo
Prof. Dr. Huiying Fan
Dr. Qing Wang

Deadline for manuscript submissions

closed (31 October 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/202727

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).